Pearce IP BioBlast w/e 26 Jan 2024
AbbVie announced it will invest US$233M in its biologics manufacturing facility in Singapore. The investment will add 24,000L of biologics…
Source: lexology.com
Alexion Soliris News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Alexion Soliris. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Alexion Soliris Today - Breaking & Trending Today
BioBlast w/e 24 Feb 23: Abbvie in hot water over Humira® pricing, Celltrion's Yuflyma® delays explained, Merck/Moderna mRNA vaccine/ Keytruda treatment, French Court overturns Novartis/Roche €444M cartel fine, Amgen's Amjevita® savings, Genetech new biologics facility, Regeneron new aflibercept product, Amgen's Bekemv® eculizumab
The Financial Times has reported that the Dutch Pharmaceutical Accountability Foundation (PAF), a public interest group, is suing AbbVie for…
Source: lexology.com
One Year Post-Launch of Argenx's Vyvgart for gMG, US Neurologists Confused on Best Approach to Treatment Dosing Schedules, According to Spherix Global Insights
/PRNewswire/ -- Argenx's launch of Vyvgart (efgartigimod) has been a success, with global first-year revenue of ~$400 million USD. As the second biologic...
Source: prnewswire.com
Argenx's Vyvgart and Alexion's Ultomiris Go Toe-to-Toe in Generalized Myasthenia Gravis, According to Spherix Global Insights
/PRNewswire/ -- Competition in the generalized myasthenia gravis (gMG) market is heating up with the launches of argenx's Vyvgart and Alexion's Ultomiris...
Source: prnewswire.com
Argenx's Vyvgart and Alexion's Ultomiris Go Toe-to-Toe in Generalized Myasthenia Gravis, According to Spherix Global Insights
/PRNewswire/ -- Competition in the generalized myasthenia gravis (gMG) market is heating up with the launches of argenx's Vyvgart and Alexion's Ultomiris...
Source: prnewswire.com